Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zura BioFRA:94E -1.29%25 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:94E with a GF Score™ of 25/100. Among 940 Biotechnology companies, Zura Bio ranks worse than 106382.87% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zura Bio's EBITDA for the
three
months ended in Mar. 2026 was €-22.04 Mil. Zura Bio's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, Zura Bio's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
Zura Bio (FRA:94E) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zura Bio EBITDA Margin % Related Terms
Zura Bio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zura Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:94E vs ASMB, ARTV, EIKN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Zura Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zura Bio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zura Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zura Bio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zura Bio (FRA:94E) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zura Bio and its competitors. According to the industry distribution chart, Zura Bio ranks #999999 out of 940 companies in the Biotechnology industry.
Is Zura Bio's EBITDA Margin % too high?
Zura Bio's current EBITDA Margin % is 0.00%. Based on the distribution chart, Zura Bio ranks #999999 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zura Bio has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Zura Bio's EBITDA Margin % compare to ASMB and ARTV?
According to the Biotechnology industry distribution chart, Zura Bio ranks #999999 out of 940 companies for EBITDA Margin %. This places Zura Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zura Bio and its competitors. Zura Bio's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zura Bio stock overvalued right now?
Zura Bio (FRA:94E) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Zura Bio's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zura Bio (FRA:94E), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
25GF Score
Get the complete analysis for FRA:94E
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:94E has been successfully added to your 
